Abstract
Context Some patients with classic congenital adrenal hyperplasia (CAH) survive without glucocorticoid treatment. Increased precursor concentrations in these patients might lead to higher free (biological active) cortisol concentrations by influencing the cortisol-protein binding. In 21-hydroxylase deficiency (21OHD), the most common CAH form, accumulated 21-deoxycortisol (21DF), a precursor steroid, may further increase glucocorticoid activity. Both mechanisms could explain the low occurrence of symptoms in some untreated classic CAH patients.
Objective Establishment and validation of an LC-MS/MS method for (free) cortisol and (free) 21DF to quantify these steroids in untreated patients with classic CAH (n=29), non-classic CAH (NCCAH, n=5), other forms of adrenal insufficiency (AI, n=3), and controls (n=11) before and 60 minutes after Synacthen® administration.
Results Unstimulated total cortisol levels of untreated classic CAH patients (median 109 nmol/L) were lower compared to levels in untreated NCCAH patients (249 nmol/L, p=0.010) and controls (202 nmol/L, p=0.016), but free cortisol concentrations were similar. Basal free 21DF levels were high in 21OHD patients (median 5.32 nmol/L) and undetectable in AI patients and controls (<0.19 nmol/L). After Synacthen® administration, free concentrations of 21DF -but not cortisol-increased only in patients with 21OHD.
Conclusions Free cortisol levels were similar in classic CAH compared to controls and NCCAH patients, suggesting a comparable availability of cortisol. Additionally, 21OHD patients produce high levels of the glucocorticoid 21DF, possibly explaining the low occurrence of symptoms in some classic 21OHD patients. Free cortisol and (free) 21DF levels should be considered in the clinical evaluation of adrenal insufficiency in patients with CAH.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by International Fund Congenital Adrenal Hyperplasia (IFCAH).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The local medical ethics committee of the Radboud university medical center gave ethical approval for this work (case number 2021-12944).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding: This work was funded by International Fund Congenital Adrenal Hyperplasia (IFCAH).
Disclosures: The authors have nothing to disclose.
Data Availability
All data produced in the present study are available upon reasonable request to the authors after acceptance